Abstract:Background: A number of oncoproteins and tumor suppressors are known to be neddylated, but whether the neddylation pathway is entirely activated in human cancer remains unexplored. Methods: NEDD8-activating enzyme (NAE) (E1) and NEDD8-conjugating enzyme (E2) expression and global-protein neddylation were examined by immunohistochemistry, immunoblotting, and real-time polymerase chain reaction analysis. Cell proliferation, clonogenic survival, migration, and motility in vitro, as well as tumor formation and metastasis in vivo, were determined upon neddylation inhibition by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Survival was analyzed with Kaplan-Meier methods and compared by the log-rank test. All statistical tests were two-sided. Results: The entire neddylation pathway, including NEDD8-activating enzyme E1, NEDD8-conjugating enzyme E2, and global-protein neddylation, is overactivated in both lung adenocarcinoma and squamous-cell carcinoma. Compared with lung adenocarcinoma patients with low expression, those with high expression had worse overall survival (NEDD8-activating enzyme E1 subunit 1 [NAE1]: hazard ratio [HR] = 2.07, 95% confidence interval [CI] = 0.95 to 4.52, P = .07; ubiquitin-conjugating enzyme E2M (UBC12): HR = 13.26, 95% CI = 1.77 to 99.35, P = .01; global protein neddylation: HR = 3.74, 95% CI = 1.65 to 8.47, P = .002). Moreover, inhibition of neddylation by the NAE inhibitor MLN4924 statistically significantly suppressed proliferation, survival, migration, and motility of lung cancer cells in vitro and tumor formation and metastasis in vivo. At the molecular level, MLN4924 inactivated Cullin-RING E3 ligases, led to accumulation of tumor-suppressive Cullin-RING E3 ligase substrates and induced phorbol-12-myristate-13-acetate-induced protein 1 (NOXA)-dependent apoptosis or cellular senescence. Conclusions: Our study highlights the overactivated neddylation pathway in lung cancer development and as a promising therapeutic target.

Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions

NAE modulators: A potential therapy for gastric carcinoma

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

Protein Neddylation and Its Alterations in Human Cancers for Targeted Therapy.

Progress in the researches for antitumor NEDD8 activating enzyme inhibitors

Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways

Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation (Review)

Protein Neddylation in Lung Tumorigenesis: Target Validation and Targeted Therapy

NEDD8-conjugating Enzyme E2s: Critical Targets for Cancer Therapy

Targeting cullin neddylation for cancer and fibrotic diseases

The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway

Anticancer Drug Discovery by Targeting Cullin Neddylation

Overactivated neddylation pathway as a therapeutic target in lung cancer

The many substrates and functions of NEDD4-1

Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy

Neddylation Regulates Macrophages and Implications for Cancer Therapy

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

Identification of novel benzoyl hydrazine derivatives as activators of neddylation pathway to inhibit the tumor progression in vitro

Advances of relationship between protein Neddylation and cancer

Promoting Tumorigenesis in Nasopharyngeal Carcinoma, NEDD8 Serves As a Potential Theranostic Target